Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)

NCT06907290 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06907290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 25, 2025
Completion date
September 30, 2029
Enrollment
150 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d infection